304 related articles for article (PubMed ID: 23430197)
1. Sclerostin and DKK1 in primary hyperparathyroidism.
Viapiana O; Fracassi E; Troplini S; Idolazzi L; Rossini M; Adami S; Gatti D
Calcif Tissue Int; 2013 Apr; 92(4):324-9. PubMed ID: 23430197
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia.
Kaji H; Imanishi Y; Sugimoto T; Seino S
Exp Clin Endocrinol Diabetes; 2011 Jul; 119(7):440-4. PubMed ID: 21667439
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism.
Moosgaard B; Vestergaard P; Heickendorff L; Melsen F; Christiansen P; Mosekilde L
Clin Endocrinol (Oxf); 2005 Nov; 63(5):506-13. PubMed ID: 16268801
[TBL] [Abstract][Full Text] [Related]
5. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.
Gatti D; Viapiana O; Adami S; Idolazzi L; Fracassi E; Rossini M
Bone; 2012 Mar; 50(3):739-42. PubMed ID: 22178539
[TBL] [Abstract][Full Text] [Related]
6. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls.
van Lierop AH; Witteveen JE; Hamdy NA; Papapoulos SE
Eur J Endocrinol; 2010 Nov; 163(5):833-7. PubMed ID: 20817762
[TBL] [Abstract][Full Text] [Related]
7. Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis.
Rossini M; Viapiana O; Zanotti R; Tripi G; Perbellini O; Idolazzi L; Bonifacio M; Adami S; Gatti D
Calcif Tissue Int; 2015 May; 96(5):410-6. PubMed ID: 25694360
[TBL] [Abstract][Full Text] [Related]
8. In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density.
Rossini M; Viapiana O; Adami S; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Orsolini G; Gatti D
Clin Exp Rheumatol; 2015; 33(1):77-83. PubMed ID: 25438096
[TBL] [Abstract][Full Text] [Related]
9. The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.
Gatti D; Viapiana O; Idolazzi L; Fracassi E; Rossini M; Adami S
J Clin Endocrinol Metab; 2011 May; 96(5):1555-9. PubMed ID: 21367927
[TBL] [Abstract][Full Text] [Related]
10. Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD.
Behets GJ; Viaene L; Meijers B; Blocki F; Brandenburg VM; Verhulst A; D'Haese PC; Evenepoel P
PLoS One; 2017; 12(5):e0176411. PubMed ID: 28493902
[TBL] [Abstract][Full Text] [Related]
11. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
Thambiah S; Roplekar R; Manghat P; Fogelman I; Fraser WD; Goldsmith D; Hampson G
Calcif Tissue Int; 2012 Jun; 90(6):473-80. PubMed ID: 22527202
[TBL] [Abstract][Full Text] [Related]
12. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
[TBL] [Abstract][Full Text] [Related]
13. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
[TBL] [Abstract][Full Text] [Related]
14. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Sclerostin and Dickkopf-1 levels in patients with fluorine bone injury.
Wang W; Xu J; Liu K; Liu X; Li C; Cui C; Zhang Y; Li H
Environ Toxicol Pharmacol; 2013 May; 35(3):402-7. PubMed ID: 23467116
[TBL] [Abstract][Full Text] [Related]
16. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study.
Ardawi MS; Al-Sibiany AM; Bakhsh TM; Rouzi AA; Qari MH
Osteoporos Int; 2012 Jun; 23(6):1789-97. PubMed ID: 22041864
[TBL] [Abstract][Full Text] [Related]
17. Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis.
Gatti D; Viapiana O; Idolazzi L; Fracassi E; Ionescu C; Dartizio C; Troplini S; Kunnathully V; Adami S; Rossini M
Bone; 2014 Oct; 67():189-92. PubMed ID: 25003812
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients.
Cejka D; Jäger-Lansky A; Kieweg H; Weber M; Bieglmayer C; Haider DG; Diarra D; Patsch JM; Kainberger F; Bohle B; Haas M
Nephrol Dial Transplant; 2012 Jan; 27(1):226-30. PubMed ID: 21613383
[TBL] [Abstract][Full Text] [Related]
19. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
[TBL] [Abstract][Full Text] [Related]
20. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
